title: Transient reduction of PTI-1 expression by short interfering RNAs inhibits the growth of human prostate cancer cell lines.
abstract: The prostate tumor-inducing gene 1 (PTI-1) was originally identified by differential ribonucleic acid (RNA) display in human prostate carcinoma. PTI-1 is expressed in human prostate carcinoma but not in benign prostate hypertrophy or normal prostate tissue. PTI-1 may be a member of oncogenes that could affect protein translation and contribute to carcinoma development in human prostate. To investigate the role of PTI-1 in human prostate carcinoma, we constructed three different short interfering RNA (siRNA) vectors (pSilencer3.1-neo-Yu Lei [YL]1-2, -YL3-4 and -YL5-6), each of which was transfected into DU145 and PC3 human prostate cancer cell lines. Among these siRNAs, only pSilencer3.1-neo-YL1-2 could almost completely block the expression of PTI-1 in these two cell lines. The growth of the cell lines was then evaluated after transfection. The proliferation rate was retarded in DU145 and PC3 cells transfected with pSilencer3.1-neo-YL1-2, compared with the cells transfected with a control vector; namely, about 88.6% of DU145 and 80.2% of PC3 cancer cells were blocked at the G1 phase when transfected with pSilencer3.1-neo-YL1-2, compared to 62.0% in DU145 cells and 51.7% in PC3 cells, transfected with the control vector. Moreover, 68.3% of DU145 cells and 72.3% of PC3 cells were induced into apoptosis, while in control transfection, the population was 26.6% in DU145 cells and 28.4% in PC3 cells. These results indicate that blocking PTI-1 expression can inhibit the growth of certain prostate cancer cell lines. We suggest that PTI-1 may serve as a target for the gene-based therapy of human prostate carcinoma.
authors.affiliation: Department of Urology, Xi-jing Hospital, the Fourth Military Medical University, Xi'an, 700132, China. yulei1@fmmu.ed.cn
authors.forename: Lei
authors.initials: L
authors.lastname: Yu
authors.forename: Guojun
authors.initials: G
authors.lastname: Wu
authors.forename: Liguo
authors.initials: L
authors.lastname: Wang
authors.forename: He
authors.initials: H
authors.lastname: Wang
authors.forename: Geng
authors.initials: G
authors.lastname: Zhang
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics / Q000473:pathology* / Q000517:prevention & control; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D017931:DNA Primers / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D020868:Gene Silencing; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D008297:Male; D015513:Oncogene Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics; D020648:Peptide Elongation Factor 1 / Q000037:antagonists & inhibitors* / Q000235:genetics; D011471:Prostatic Neoplasms / Q000235:genetics / Q000473:pathology* / Q000517:prevention & control; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000494:pharmacology*; D014162:Transfection
chemical_list: D017931:DNA Primers; C094814:EEF1A1 protein, human; D015513:Oncogene Proteins; D020648:Peptide Elongation Factor 1; D034741:RNA, Small Interfering